Papers/PMID:18922041
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.
PLoS medicine2008The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
phylloquinone — decreases all-site cancer incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Cancer incidence was lower in the vitamin K group than in the placebo group (three versus 12, p = 0.02; HR = 0.25, 95% CI 0.07 to 0.89).”
Quoted verbatim from Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.. - Study
- RCT
- Dose
- 5 mg vitamin K1 daily
- Population
- Postmenopausal women with osteopenia, vitamin D replete, receiving calcium and vitamin D in both arms; follow-up up to 4 years
Effect 0.25 hazard ratio, 95% CI 0.07 to 0.89
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.2008PMID:18922041Permalink